Queratopatia Relacionada com Belantamab Mafodotina

Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther. 2020 Dec;9(4):889-911. doi: 10.1007/s40123-020-00280-8. Epub 2020 Jul 25. Erratum in: Ophthalmol Ther. 2020 Sep 12.

Lonial S., Nooka AK., Thulasi P. et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal (2021) 11:103

Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol. 2021 Oct 3;14(1):159. doi: 10.1186/s13045-021-01172-5.

Matsumiya W, Karaca I, Ghoraba H, Akhavanrezayat A, Mobasserian A, Hassan M, Regenold J, Yasar C, Liedtke M, Kitazawa K, Nguyen QD. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. Am J Ophthalmol Case Rep. 2021 Jun 9;23:101133. doi: 10.1016/j.ajoc.2021.101133.

Chuang K, Pineda R, Liu S. Belantamab mafodotin associated corneal microcyst-like epithelial changes. Am J Ophthalmol Case Rep. 2022 Feb 2;25:101392. doi:10.1016/j.ajoc.2022.101392.